Amarin (AMRN) Issused Patent 8,324,195 for Vascepa
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp Plc (NASDAQ: AMRN) announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa® (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 13/349,150. On September 10, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No.8,324,195, has a term that expires no earlier than in 2030.
"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Amarin now has 10 U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.
"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Amarin now has 10 U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Getty Realty discloses separation terms for departing accounting officer
- Arena Group to rename as Paradium.AI, ticker changing to PAAI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
